152 related articles for article (PubMed ID: 15465141)
1. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.
Kouloulias VE; Giraud JY; Davis BJ; Dusserre A; Zurlo A; Bolla M
Radiother Oncol; 2004 Oct; 73(1):11-20. PubMed ID: 15465141
[TBL] [Abstract][Full Text] [Related]
2. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
Matzinger O; Poortmans P; Giraud JY; Maingon P; Budiharto T; van den Bergh AC; Davis JB; Musat E; Ataman F; Huyskens DP; Gulyban A; Bolla M;
Radiother Oncol; 2009 Mar; 90(3):285-90. PubMed ID: 19038468
[TBL] [Abstract][Full Text] [Related]
3. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.
Baumert BG; Brada M; Bernier J; Kortmann RD; Dehing-Oberije C; Collette L; Davis JB
Radiother Oncol; 2008 Aug; 88(2):163-72. PubMed ID: 18455252
[TBL] [Abstract][Full Text] [Related]
4. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
Kassim I; Dirkx ML; Heijmen BJ
Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
8. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
Beckendorf V; Guérif S; Le Prisé E; Cosset JM; Lefloch O; Chauvet B; Salem N; Chapet O; Bourdin S; Bachaud JM; Maingon P; Lagrange JL; Malissard L; Simon JM; Pommier P; Hay MH; Dubray B; Luporsi E; Bey P
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1056-65. PubMed ID: 15519775
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
[TBL] [Abstract][Full Text] [Related]
11. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
Ataman F; Poortmans P; Davis JB; Bernier J; Giraud JY; Kouloulias VE; Pierart M; Bolla M
Eur J Cancer; 2004 Nov; 40(16):2411-6. PubMed ID: 15519513
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
Muren LP; Wasbø E; Helle SI; Hysing LB; Karlsdottir A; Odland OH; Valen H; Ekerold R; Johannessen DC
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1034-41. PubMed ID: 18249502
[TBL] [Abstract][Full Text] [Related]
13. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
14. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
16. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
17. [Conformal radiotherapy for patients with clinical stage T1-T3 prostate cancer].
Majewski W; Miszczyk L; Zajusz A
Przegl Lek; 2004; 61(5):503-8. PubMed ID: 15515815
[TBL] [Abstract][Full Text] [Related]
18. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
19. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy.
Fiorino C; Dell'Oca I; Pierelli A; Broggi S; De Martin E; Di Muzio N; Longobardi B; Fazio F; Calandrino R
Radiother Oncol; 2006 Mar; 78(3):276-82. PubMed ID: 16546279
[TBL] [Abstract][Full Text] [Related]
20. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
